ARTICLE | Clinical News
LDP-341 (PS-341): Began Phase II study
March 5, 2001 8:00 AM UTC
Millennium Pharmaceuticals Inc. (MLNM), Cambridge, Mass. Product: LDP-341 ( PS-341) Business: Cancer Therapeutic category: Apoptosis, Cell proliferation Target: 20S/26S proteasome Description: Small ...